Uni-Bio Science Acquires Rights to Jiangsu Hansoh's Diabetes Drug

Uni-Bio Science of Hong Kong acquired worldwide rights to make and commercialize Jiangsu Hansoh Pharma's mitiglinide, an oral treatment for type 2 diabetes. Hansoh has already won several provincial tenders for the drug. Using API from Hansoh, Uni-Bio will manufacture the drug in its CGMP-certified plant in Beijing. Uni-Bio will seek commercialization partners for ex-China markets. More details.... Stock Symbol: (HK: 690) Share this with colleagues: // //